Ranibizumab therapy for neovascular age-related macular degeneration.
about
CNTF mediates neurotrophic factor secretion and fluid absorption in human retinal pigment epitheliumSynthesis and mechanistic studies of a novel homoisoflavanone inhibitor of endothelial cell growthRepression of choroidal neovascularization through actin cytoskeleton pathways by microRNA-24.Ferrochelatase is a therapeutic target for ocular neovascularization.Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials.The first synthesis of the antiangiogenic homoisoflavanone, cremastranoneThe Chinese medicine formula HB01 reduces choroidal neovascularization by regulating the expression of vascular endothelial growth factor.Low-dose lipopolysaccharide pretreatment suppresses choroidal neovascularization via IL-10 induction.Risk- and non-risk-associated variants at the 10q26 AMD locus influence ARMS2 mRNA expression but exclude pathogenic effects due to protein deficiency.Quantifying disrupted outer retinal-subretinal layer in SD-OCT images in choroidal neovascularization.Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.The COX-2-Selective Antagonist (NS-398) Inhibits Choroidal Neovascularization and Subretinal Fibrosis.Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth FactorLet-7 contributes to diabetic retinopathy but represses pathological ocular angiogenesis.Nonsteroidal anti-inflammatory drugs for retinal disease.Let There Be Light: Gene and Cell Therapy for Blindness.Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium.Synthesis and Biological Evaluation of Novel Homoisoflavonoids for Retinal NeovascularizationReal-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study.Six-year outcomes in neovascular age-related macular degeneration with ranibizumab.Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration.Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration.Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.Diabetic retinopathy is a neurodegenerative disorder.4-Hydroxy-7-oxo-5-heptenoic Acid Lactone Induces Angiogenesis through Several Different Molecular Pathways.Preparation and evaluation of human choroid extracellular matrix scaffolds for the study of cell replacement strategies.Effects of p75 neurotrophin receptor on regulating hypoxia-induced angiogenic factors in retinal pigment epithelial cells.Structural and molecular changes in the aging choroid: implications for age-related macular degeneration.Comparison of microbiology and visual outcomes of patients undergoing small-gauge and 20-gauge vitrectomy for endophthalmitis.Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab.Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivoStrand and Cell Type-specific Function of microRNA-126 in Angiogenesis[Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections].Electrophysiological toxicity testing of VEGF Trap-Eye in an isolated perfused vertebrate retina organ culture model.Evaluation of sFLT1 protein levels in human eyes with the FLT1 rs9943922 polymorphism.C-Reactive Protein As a Mediator of Complement Activation and Inflammatory Signaling in Age-Related Macular Degeneration.Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
P2860
Q24337795-6D53A5D1-0508-47B1-81C3-334BC01A1DF9Q28538093-BCD4BC0C-F360-4D15-8887-78E39D62B74BQ30571075-D383BACC-4DFE-4C37-BD37-D90BF5621DEEQ33749012-84D26E93-0760-41E9-A8F1-B71593898D58Q33795040-2E3F0EDB-6EA3-49C8-B02A-87828395474BQ34207028-AB0B9026-922A-4AF6-8850-C4EEFE7F6C28Q34296110-EA666636-A7D3-45BF-AB62-2A3B583E8A80Q34339633-18E30483-3112-4675-A173-B3A32262A1D9Q34627058-51EE0A52-82A1-4707-B484-97CABB6EA20CQ35102996-02A70D2B-B6D2-4F14-BFDA-9FACFACB4AF6Q35705156-77EDDDE8-AB8A-4089-957C-B116F774039CQ35892555-57809B1E-5B0B-430D-B60E-8AEF032830AAQ35904896-5A8385AD-4A6D-443D-A8C0-379A638D86FCQ36393604-4BB9405E-6078-4C52-A369-A8D8B88C9AF4Q36567310-49A09C2B-1AB6-4D22-A961-A0849FC3AE14Q36654534-3B1ABCB9-C339-4C03-B815-1758B43E0DA8Q36669193-DBB423D9-51B2-4DC4-B636-460FF10B23B9Q37093337-6B041D54-611E-421F-A3A7-48860DE366C3Q37211244-E4DB4160-7FE0-4049-8493-D1CE2800F42EQ37578627-D0AE8B0E-1646-42D4-B446-BE3C931ADBC7Q37980818-AB25BF93-5D93-4754-A7C1-6C1B2D9F144DQ38030051-07EDD3C7-6C15-4253-82C9-6CE501E71044Q38094076-BA4F842C-8C93-4EE0-9D9D-C092E2893D47Q38730604-92AADFC8-9C4E-47DE-806C-FFD2884C6DD8Q38733835-ED7B9EE0-FC6E-46E8-82F7-AC775A70C42DQ38797156-086C2E92-EC78-4120-9FC2-B2939008687CQ38958610-F55E78BE-1B32-47AF-A949-CF6831CD8D96Q38975097-F56F9EBB-171C-492C-B360-3A68D694F630Q40799208-5F0E1890-1229-489A-B660-843CF20303D4Q41091625-E4B00CF9-37D8-48E5-A789-8A3B1EE1DFAAQ41587469-48DAFE28-EDD0-4A2D-8EAC-7BAB860478AEQ41653973-1F3DB17B-55B1-4AF0-AF29-216D9C366094Q44345438-0E3A8560-4392-4351-AC17-98462C91050DQ45950125-EEC962C7-9B41-421C-AF92-431E3A37F12BQ47741873-61820BFB-A1A0-4BA6-8FC8-20D2CC96F191Q51758276-5D587071-4C88-4F69-83F2-EBF96B472756Q59126137-540A45EA-F6A9-4EF3-A53C-C95CF8F710D9
P2860
Ranibizumab therapy for neovascular age-related macular degeneration.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ranibizumab therapy for neovascular age-related macular degeneration.
@en
Ranibizumab therapy for neovascular age-related macular degeneration.
@nl
type
label
Ranibizumab therapy for neovascular age-related macular degeneration.
@en
Ranibizumab therapy for neovascular age-related macular degeneration.
@nl
prefLabel
Ranibizumab therapy for neovascular age-related macular degeneration.
@en
Ranibizumab therapy for neovascular age-related macular degeneration.
@nl
P356
P1476
Ranibizumab therapy for neovascular age-related macular degeneration.
@en
P304
P356
10.1056/NEJMCT1000495
P407
P577
2010-10-01T00:00:00Z